When a technology starts being mentioned at the sector’s leading congresses and in specialist press without the brand paying for it as advertising, it is a different signal from a launch campaign: it means physicians and journalists consider it relevant in its own right. That is what began to happen with Nesai and AI facial ultrasound over the course of 2026.
At congresses: TechAiDerm, SELMQ and A3 Allergan Aesthetics
At TechAiDerm 2026, Dr. Marta Vilavella presented Nesai as an innovation in aesthetic dermatology, and Dr. Isabel Bové also presented at the congress. Dr. Francisco de Cabo took an active part alongside figures such as Dr. Carlos Morales Raya and the president of SEME (the Spanish Society of Aesthetic Medicine).
At the SELMQ 2026 congress, Dr. Isabel Bové presented results based on Nesai reports to the aesthetic and laser medicine community.
At the Allergan Aesthetics A3 event 2026 (9th edition, with Alma Lasers and IrrAdia), Dr. Carlos Morales Raya (a leading dermatologist in Madrid, introduced by Dr. Fernando Urdiales) focused on understanding the biology of the skin before treating it:
“In this evidence-based aesthetic medicine, Nesai’s AI makes it possible to quantify the dermis and hypodermis to personalise treatments and achieve more ethical, precise and measurable results.”
When introducing him, Dr. Urdiales himself recalled that systematising the ultrasound patterns of filler materials is nothing new: it goes back to a pioneering article published in 2021 by Dr. Francisco de Cabo and Dr. Isabel Bové, now co-founders of Nesai.
Dr. Ofelia Casanueva gave a talk on the objective assessment of skin quality, showing with Nesai Derm how to quantify the changes after combining Alma Lasers’ Hybrid® technology with Skinvive® by Juvéderm® (Allergan Aesthetics), through the pixel histogram of the dermis (LEP, MEP and HEP), compared before and after treatment. And with Nesai Face, the relationship between previous fillers and the condition of the skin.
The session was closed by Dr. Iratxe Díaz, moderator and aesthetic medicine KOL, with an idea that sums up the underlying reason: clinical excellence means personalising each treatment according to the real condition of the skin and an objective assessment, with maximum safety and “zero risk” as a working philosophy.
Also at A3 Allergan, the company placed Nesai alongside VISIA and standardised photography as one of the recognised methods for measuring skin quality (“Skin Quality”), a significant reference coming from one of the major companies in the aesthetics sector, not from a Nesai channel.
Dr. Marta Vilavella presenting Nesai as an innovation in aesthetic dermatology at TechAiDerm 2026.
Dr. Isabel Bové presenting results based on Nesai reports at the SELMQ 2026 congress.
Dr. Fernando Urdiales, at the Allergan Aesthetics A3 event 2026.
Dr. Ofelia Casanueva, with Nesai Face, at the same event.
In the specialist press
Press coverage has been just as specific. Telva, in a feature on how artificial intelligence is changing aesthetic medicine (Nov. 2025), quotes Nesai’s own co-founder and CEO, David Campos (quotes translated from Spanish):
“AI acts as a co-pilot, improving diagnostic capabilities, reducing uncertainty and raising the standards of safety and traceability that are essential in modern aesthetic medicine.”
Dr. Tufet, in the same feature, sums it up from the consultation room:
“In this new scenario, data replaces images. The system builds and compares millions of cases to show, objectively, the condition of the skin, and assesses the condition and progress of the treatments carried out.”
Consalud, a specialist health outlet, wrote about Nesai in an article on artificial intelligence and safety in aesthetic medicine:
“With Nesai’s AI, diagnoses no longer depend solely on visual observation or photographic images.”
And ¡Hola! magazine, in a feature on new facial treatments, put the real adoption of the technology into figures:
“This advanced technology is already present in more than 50 clinics in Spain.”
Why this matters beyond the press release
Neither congresses nor the press mention technologies out of courtesy: they mention them when they bring something verifiable to the sector’s debate. In this case, objective (ultrasound) data where before there was only visual assessment. That is the same reason why aesthetic medicine and dermatology clinics across Spain already use Nesai in their daily practice. You can see the full list in find a clinic.
If you are a clinic and want to know whether your ultrasound machine is compatible, or a company interested in validating a product’s efficacy with objective ultrasound data, talk to the team.
